← All organizations
Highest phase reached
Phase 3
First clinical trial
Jun 1, 2005Last known activity
Jul 15, 2025
Timeline
1990s
- Jul 1, 1995
Infinity Pharmaceuticals, Inc.— Founded
2020s
- Jul 14, 2023
MEI Pharma— Acquired
Drugs by trial phase (40 distinct, 51 trials)
Phase 3 (1 own, 9 via acquisition)
Phase 2 (12 own, 9 via acquisition)
Phase 1 (6 own, 3 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Adrenocortical Carcinoma
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carcinoma, Transitional Cell
- Chondrosarcoma
- Gastrointestinal Stromal Tumors
- Head and Neck Neoplasms
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Liposarcoma
- Lung Neoplasms
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, T-Cell
- Melanoma
- Mesothelioma
- Multiple Myeloma
- Neoplasms
- Neoplasms, Plasma Cell
- Neoplasms, Squamous Cell
- Pancreatic Neoplasms
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Primary Myelofibrosis
- Prostatic Neoplasms
- Sarcoma
- Triple Negative Breast Neoplasms
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (49)
- NCT07035652Lead sponsorPhase 1Jul 15, 2025
- NCT06981091Lead sponsorPhase 2May 16, 2025
- NCT06978699Lead sponsorPhase 2Apr 30, 2025
- NCT06272747Lead sponsorPhase 1Feb 22, 2024
- NCT06236841Lead sponsorPhase 1Jan 26, 2024
- NCT06204419Lead sponsorPhase 1Dec 26, 2023
- NCT05946876Lead sponsorPhase 1Jul 19, 2023
- NCT03980041OfficialPhase 2Jun 30, 2019
- NCT03980041Study directorPhase 2Jun 30, 2019
- NCT03980041Lead sponsorPhase 2Jun 30, 2019
- NCT03961698Lead sponsorPhase 2Jun 1, 2019
- NCT03719326CollaboratorPhase 1Oct 15, 2018
- NCT02640833CollaboratorPhase 1Jul 1, 2016
- NCT02637531Lead sponsorPhase 1Dec 1, 2015
- NCT02637531Study directorPhase 1Dec 1, 2015
Details
- Founded
- Cambridge, MA, US Jul 1, 1995
- Last known activity
- Jul 15, 2025